Morepen LaboratoriesQ3 FY22

Morepen Laboratories Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹94.66P/E: 27.5Market Cap: ₹5.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company has maintained a historical CAGR revenue growth of around 25%, currently achieving 30% growth, and is comfortable sustaining 20-30% CAGR going forward.
  • Medical devices segment has grown at a CAGR of approximately 41-46% and is expected to continue strong growth with capacity expansions and wider market reach.
  • Online sales have surged significantly, with a 441% increase quarter-on-quarter and 30-40% ongoing quarterly growth, indicating strong future momentum.
  • Expansion in API production capacity planned from 300 KL to 1000 KL over 3 years to meet growing demand, enabling exponential sales growth through new molecule opportunities.
  • New product launches (e.g., US FDA-approved Fexofenadine, Dapagliflozin, fertility range) and increased marketing investments are expected to further drive topline growth.
  • The forthcoming authorization for Sputnik vaccine production could open a substantial new revenue stream, though dependent on bulk supply availability.
  • Strategic focus on global markets, particularly in neighboring countries and beyond, to capture larger market share.

See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company is open to raising capital but has not started any formal process yet (Page 13).
  • Informal discussions are ongoing with associates and advisors regarding fundraising (Page 13).
  • There is openness to bringing in equity players either in the medical devices subsidiary or in the parent company (Page 22).
  • No specific timelines or amounts have been provided; plans will be announced once finalized (Page 13, 22).
  • The company is also open to partnerships, M&A, and inviting new investors to the board to support growth (Page 22).
  • Previously, inability to access the market limited fundraising, but the current situation is described as a "historical moment" allowing for capital infusion (Page 22).
  • No mention of new debt raising; focus appears to be more on equity capital raising.

See what Morepen Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex of around ₹22 Crores planned for the year, including ₹12 Crores spent and ₹5 Crores work in progress (Page 20).
  • ₹45 Crores investment in medical devices over nine months, showing significant focus on this segment (Page 20).
  • Expansion planned to increase capacity from 300 KL to 1000 KL over three years for API segment, requiring additional capex (Page 19).
  • Setting up plant for ANDA and ABS, but filing is 2 years away due to validation process (Page 21).
  • Demerger of medical devices business into a separate 100% owned subsidiary to attract better capital, customers, and talent (Page 14).
  • Increased R&D spending (up 58%) primarily in API and finished dosages, with plans to ramp up further as topline grows (Page 12).
  • Heavy investments in meters and marketing for medical devices, including celebrity endorsements, to expand market reach (Pages 7, 11).
  • Open to bringing equity investors or partners via M&A to support growth, including in medical devices or parent company (Page 22).

Track Morepen Laboratories — get its next earnings analysis in your feed

How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisMorepen Laboratories
Rev 2Mar 3

How does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →